|
The International Life Sciences and Health Law Committee considers, informs and engages its members, the Section and the ABA on current and developing issues of importance in both public and private international life sciences and health law, e.g., international control of emerging and other communicable diseases; managing health care costs and privatization of health care systems; international trade and sustainable health; science, genetic testing and the workplace. The Committee also brings together lawyers from different countries whose practice areas focus on advising and counseling life science companies, such as pharmaceutical, medical device, biologics, cosmetic and food companies on regulatory issues facing those specific industries. All companies face legal and regulatory issues relating to marketing authorization, reimbursement (where applicable), privacy and human rights protections, and pricing/fair competition, to name a few. However, each country and region has its own set of rules and requirements, and the Committee allows participants the opportunity to network with their counterparts in other countries and educate them, as well as their clients, on the respective countries' laws.
|
